Eli Lilly (LLY) Reports Strong Phase 1 Ovarian Cancer Data

What happened: Eli Lilly (NYSE: LLY) reported new Phase 1 data for Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer patients, showing a high confirmed response rate and disease control rate. Why it matters: The content frames the early results as support for the claim that non-incretin franchises, including oncology, can become meaningful alongside cardiometabolic drugs. Market: -2.5% today ($1,273.46), +18.3% YTD, 0.9x vol — as of 23:45 UTC

Eli Lilly (NYSE: LLY) reported new Phase 1 data for Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer patients, showing a high confirmed response rate and disease control rate.

The content frames the early results as support for the claim that non-incretin franchises, including oncology, can become meaningful alongside cardiometabolic drugs. Market: -2.5% today ($1,273.46), +18.3% YTD, 0.9x vol — as of 23:45 UTC